Results 161 to 170 of about 222,357 (321)
Treatment-wise Glioblastoma Survival Inference with Multi-parametric Preoperative MRI [PDF]
In this work, we aim to predict the survival time (ST) of glioblastoma (GBM) patients undergoing different treatments based on preoperative magnetic resonance (MR) scans. The personalized and precise treatment planning can be achieved by comparing the ST of different treatments.
arxiv
Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects. [PDF]
A. Fontana+3 more
openalex +1 more source
LNPsD18, a cationic liposome that enhances antigen‐presenting cell uptake in the spleen and tumor without targeting ligands is developed. Co‐delivering neoantigens and a TLR9 agonist significantly improve DC activation, tumor immunity, and survival in liver and colorectal cancer models, demonstrating the importance of dual‐site APC targeting for cancer
Yu Xu+12 more
wiley +1 more source
STING Agonists and How to Reach Their Full Potential in Cancer Immunotherapy
STING agonists show promise in preclinical studies in boosting an anti‐tumor response using the immune system. However, different limitations remain, and future research is needed to better understand how STING activation impacts the tumor microenvironment, identify effective combination strategies, and determine the best tumor types for STING agonist ...
Laura Gehrcken+3 more
wiley +1 more source
S-B-2. Glioblastoma Multiforme: Surgery and Its Follow up
Yasuhiko Matsukado+4 more
openalex +2 more sources
HDAC6 and USP9X Control Glutamine Metabolism by Stabilizing GS to Promote Glioblastoma Tumorigenesis
Glioblastoma (GBM) growth relies on glutamine synthetase (GS), which is stabilized by histone deacetylase 6 (HDAC6) and deubiquitinated by ubiquitin‐specific peptidase 9, X‐linked (USP9X). HDAC6 promotes GS deacetylation, while USP9X removes its K48‐linked polyubiquitination, enhancing GS stability.
Go Woon Kim+9 more
wiley +1 more source
A novel “prof” cocktail therapy is designed. It screens antigens, selects personalized antigen panels, engineers optimized CAR‐Vδ1 T cells, and tests in patient‐derived GBM organoids, offering hope for effective CAR‐T drugs against heterogeneous solid tumors. Abstract Various challenges, including tumor heterogeneity and inadequate T cell infiltration,
Guidong Zhu+12 more
wiley +1 more source
Prodrugs of the Archetypal Dynamin Inhibitor Bis‐T‐22
The Bis‐T series of compounds comprise some of the most potent inhibitors of dynamin GTPase activity yet reported, such as Bis‐T‐22 (2). The catechol moieties are believed to limit cell permeability, rendering these compounds largely inactive in cells.
Luke R. Odell+6 more
wiley +1 more source
This study presents a novel approach for intraoperative identification of the IDH1 genotype in glioma patients using a surface‐enhanced Raman scattering (SERS) probe to measure glutathione and hydrogen peroxide. By integrating AI‐driven deep learning algorithms, the method achieves rapid and accurate genotype differentiation, offering the potential to ...
Hang Yin+14 more
wiley +1 more source
Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells. [PDF]
Candece L. Gladson, D A Cheresh
openalex +1 more source